Novo Nordisk

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Novo Nordisk and other ETFs, options, and stocks.

About NVO

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. 

CEO
Maziar Mike Doustdar
CEOMaziar Mike Doustdar
Employees
68,794
Employees68,794
Headquarters
Bagsværd, Capital Region
HeadquartersBagsværd, Capital Region
Founded
1923
Founded1923
Employees
68,794
Employees68,794

NVO Key Statistics

Market cap
180.32B
Market cap180.32B
Price-Earnings ratio
11.81
Price-Earnings ratio11.81
Dividend yield
2.99%
Dividend yield2.99%
Average volume
17.17M
Average volume17.17M
High today
$41.41
High today$41.41
Low today
$38.87
Low today$38.87
Open price
$40.06
Open price$40.06
Volume
25.02M
Volume25.02M
52 Week high
$81.44
52 Week high$81.44
52 Week low
$35.12
52 Week low$35.12

NVO News

Simply Wall St 1d
Assessing Novo Nordisk Valuation As Recent Returns Show Signs Of Fading Momentum

Advertisement Recent performance context for Novo Nordisk Novo Nordisk (NYSE:NVO) has been trading around $38.52, with a 1 day return of about 1.6% and a past...

Assessing Novo Nordisk Valuation As Recent Returns Show Signs Of Fading Momentum
Nasdaq 2d
NVO Reports Strong Phase III Diabetes Data for Children & Adolescents

Novo Nordisk NVO announced positive top-line results from the phase IIIa PIONEER TEENS study, evaluating oral semaglutide, a glucagon-like peptide 1 receptor ag...

NVO Reports Strong Phase III Diabetes Data for Children & Adolescents
Investor's Business Daily 2d
Battle Of The Weight-Loss Pills Continues With A Shocking Twist

Technology Battle Of The Weight-Loss Pills Continues With A Shocking Twist Licensing Eli Lilly (LLY) stock skidded early Friday as Novo Nordisk's (NVO) Wegovy p...

Battle Of The Weight-Loss Pills Continues With A Shocking Twist

Analyst ratings

63%

of 35 ratings
Buy
31.4%
Hold
62.9%
Sell
5.7%

More NVO News

Nasdaq 2d
Here's Why Agios Pharmaceuticals Stock Slumped This Week (And What Investors Have to Look Forward to in 2026)

Key Points Agios' price target was lowered due to increased regulatory risk. Novo Nordisk's etavopivat outperformed Agios' mitapivat in Phase 3 trials. Agios...

Here's Why Agios Pharmaceuticals Stock Slumped This Week (And What Investors Have to Look Forward to in 2026)
TipRanks 3d
Novo Nordisk Completes Key CagriSema vs. Tirzepatide Diabetes Trial: What Investors Should Watch

Novo Nordisk (NVO) announced an update on their ongoing clinical study. Unlock hedge fund-level data and powerful investing tools for smarter, sharper decision...

Benzinga 3d
Novo Nordisk Eyes Approval For Potential First Oral GLP-1 Diabetes Pill In Young Patients

Oral Semaglutide Shows Superior Glycaemic Control The phase 3a study evaluated oral semaglutide in patients aged 10–17 years and found the drug delivered a supe...

Novo Nordisk Eyes Approval For Potential First Oral GLP-1 Diabetes Pill In Young Patients
Sherwood News 3d
Hims rises after it says it now offers “full range” of FDA-approved GLP-1s

Hims & Hers rose in early trading after it announced that it now allows its providers to prescribe medications that are fulfilled by independent pharmacies, mea...

Hims rises after it says it now offers “full range” of FDA-approved GLP-1s
Nasdaq 3d
Is Novo Nordisk's 72% Crash a Generational Buying Opportunity or a Value Trap?

Key Points Novo Nordisk once benefited from euphoric sentiment around the booming GLP-1 market. Rising competition and decelerating growth has inspired invest...

Is Novo Nordisk's 72% Crash a Generational Buying Opportunity or a Value Trap?
TipRanks 3d
Novo Nordisk announces positive top-line results from Pioneer Teens study

The company states: “Novo Nordisk (NVO) today announced positive topline results from PIONEER TEENS, a phase 3a trial evaluating oral semaglutide for type 2 dia...

The Motley Fool 3d
Forget Ozempic: This High‑Flying Device Maker Can Thrive No Matter Which Weight Loss Drug Wins

Investors looking to capitalize on the rapidly growing weight-loss market face a difficult choice. Eli Lilly (LLY +2.04%) is the leader in the field, but some w...

Forget Ozempic: This High‑Flying Device Maker Can Thrive No Matter Which Weight Loss Drug Wins

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.